Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Lambert-Eaton myasthenic syndrome (LEMS) Clinical criteria: The condition must not be any of: (i) myasthenia gravis, (ii) Guillain-Barre syndrome. Treatment criteria: Must be treated by a prescriber type identifying as at least one of the following: (i) a clinical immunologist, (ii) a neurologist, (iii) a medical practitioner working under the direct supervision of one of these mentioned specialists.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Amifampridine is a broad-spectrum potassium channel blocker.”
“Following oral administration of a single 20 or 30 mg dose of RUZURGI to healthy volunteers, the apparent oral clearance (CL/F) of amifampridine was 149 to 214 L/h, the average elimination half-life (t1/2) was 3.6 to 4.2 hours. The average t1/2 of the 3-N-acetyl amifampridine metabolite was 4.1 to 4.8 hours.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Amifampridine is not metabolised by cytochrome P450 (CYP)1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.”